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In 77 percent of patients suffering from a malignant carcinoid syndrome, administration of
the somatostatin analog, octreotide (SMS 201-995, SandostatinfR) induced clinical improve-
ment coupled with a decrease in 24-hour urinary 5-hydroxyindole acetic acid (5-HIAA). This
finding prompted an evaluation to determine the correlation between the presence of somato-
statin receptors in tumor tissue and the response to octreotide in patients with advanced,
metastatic, neuroendocrine tumors. In tissues of 31 tumors (20 carcinoid, eight islet-cell
carcinoma, three medullary thyroid carcinomas), the presence of somatostatin receptors was
analyzed by binding of the somatostatin analog 125I-Tyr3-SMS 201-995 and autoradiography.
Receptors were detected in 16 of 20 samples of carcinoid tissues; all but one patient with
receptor-positive tumors improved clinically after treatment with octreotide, and the urine
5-HIAA level was reduced a median of 63 percent (range, 39-94 percent) compared to values
before treatment. Of the receptor-negative carcinoid patients, only one showed clinical
improvement, which was minimal, and there was a negligible reduction in 5-HIAA after
octreotide therapy. All eight patients with metastatic islet-cell carcinomas were positive for
somatostatin receptors. Symptomatic improvement and a >50 percent decrease in the level of
at least one of the pathologically elevated marker hormones was seen in all eight. None of the
three patients with medullary carcinoma of the thyroid had a decrease in calcitonin, and all
three were initially somatostatin receptor-negative.
We conclude that the presence of somatostatin receptors in malignant neuroendocrine
tumor tissue appears to correlate with the response to octreotide therapy. Analysis of
somatostatin receptors in malignant neuroendocrine carcinoma tissue should be included in
future prospective clinical trials ofthis synthetic peptide.
Malignant neuroendocrine tumors arise from different organs, which include the
gastrointestinal tract, pancreas, lungs, and thyroid. The common molecular thread
linking tumors from such diverse organs is the ability of the neoplastic neuroendo-
crine cell to incorporate amines intracellularly and to decarboxylate them. As a
result, they are sometimes referred to as APUDomas (amineprecursor uptake and
decarboxylation). A number of tumors from these organs secrete one or more
hormones. Among these tumors are carcinoids, glucagonomas, gastrinomas, insuli-
nomas, VIPomas, and medullary thyroid carcinomas. These tumors often grow
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slowly, but the patient may be incapacitated or die as a result of the hormonal
syndromes.
Somatostatin is a potent inhibitor of the release of pituitary and gastrointestinal
hormones [1]. Therefore, this hormone and its synthetic longer-acting analogs have
been considered for therapy of tumors which secrete hormones. We have treated 66
patients with metastatic carcinoid tumors and have sequentially followed them after
chronic self-administration of the somatostatin analog, octreotide (SMS 201-995,
Sandostatin'), using two different protocols. Thirty-one patients were started on a
low-dose protocol of octreotide, 150 mcg subcutaneously (sc) three times daily.
Flushing was reduced in 76 percent, and diarrhea improved in 83 percent. The
median 24-hour 5-hydroxyindole acetic acid (5-HIAA) level before treatment in this
group was 203 mg (normal, 0-6 mg per 24 hours). The median reduction of5-HIAA
was 69 percent with 77 percent having a major (>50 percent) reduction [2].
Thirty-five patients with no prior exposure to octreotide were started on a high-dose
protocol of octreotide, 500 mcg subcutaneously three times daily. Flushing was
reduced in 97 percent, and diarrhea improved in 77 percent. The median 24-hour
5-HIAA level before treatment in this group was 160 mg; in 77 percent of patients,
the 5-HIAA was reduced 2 50 percent) with octreotide therapy. Considering all 66
patients then, flushing was reduced in 87 percent, diarrhea in 77 percent, and amajor
( 50 percent) reduction in 5-HIAA was seen in 77 percent (Fig. 1).
The therapeutic results in malignant islet-cell carcinomas have been similiarly
favorable, with reversal of the hormonally mediated syndromes often occurring
within the first few days or weeks after initiating therapy [3]. The results delineated
according to the pathologically elevated hormone are displayed in Fig. 2.
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The precise mechanism ofsomatostatin's effect on these tumors has not been fully
elucidated. A direct effect on tumor cells was suggested by earlier studies, which
demonstrated a high incidence of somatostatin receptors in a small number of
islet-cell carcinomas [4,5,6,7]. Tumor tissues from gastrinomas, VIPomas, and insuli-
nomas were shown to contain somatostatin receptors, which suggested that perhaps
they may be required for the therapeutic efficacy of somatostatin analog. To date,
however, there has been no systematic evaluation correlating the tumor receptor
status and in vivo hormonal response in malignant neuroendocrine tumors.
We have recently reported the incidence of receptors for somatostatin in a larger
number of islet-cell carcinomas (n = 15) and carcinoid tumors (n = 62) [8]. Fifty-
four of62carcinoid patients had somatostatin receptor-positive tumors (87 percent).
In 15 of the islet-cell carcinomas, somatostatin receptors were detected. Ofparticu-
lar interest was the observation that, in biopsies of different metastases in an
individual liver, similar densities ofsomatostatin receptorswere found. This informa-
tion, combined with the ability to obtain tumor tissue for analysis by percutaneous
needle biopsy, suggests that this technique might be prognostically significant.
The goal ofthis studywas to determine ifthe presence ofsomatostatin receptors in
tumor cells is correlated with the hormonal responsiveness offunctional neuroendo-
crine carcinomas to therapywith the somatostatin analog, octreotide.
METHODS
Patient Selection and Tissue Procurement
Samples of tumors from 31 patients with malignant neuroendocrine tumors were
obtained by surgery (n = 10) or percutaneous needle biopsy (n = 21). The diagnosis
had been established before on the basis of clinical symptoms, pathologically
elevated plasma hormone levels, and histologic examination ofthe tumor. The study
population comprised 20 patients with metastatic carcinoid tumors and the malig-
nant carcinoid syndrome, eight patients with metastatic islet-cell carcinomas, and
three patients with metastatic medullary thyroid carcinoma.
Surgical specimens were obtained from metastases or from the primary tumor ifit
was resected for palliative reasons. In some cases, both the primary tumor and
metastases were available for receptor analysis. Percutaneous needle biopsy speci-
mens of the liver were obtained with ultrasound guidance. A Bard® Biopty@!
instrument and an 18-gauge Biopty-Cut@3 biopsy needle with a sampling notch of 17
mm were used. The liver biopsy specimens, with a mean weight of 6.8 mg, were
immediately deposited in a small plastic container, which was placed on dry ice.
After the specimen had been flash-frozen, it was covered with tissue preservative.
The plastic container was then covered, and, within 15-30 minutes, the containers
were sealed in airtight plastic bags and stored at -70°C. These sampleswere shipped
in dry ice to Berne, Switzerland. The storage time of tumors at -70°C before
autoradiographic processing ranged from two to 12weeks.
Autoradiography and Quantitation ofReceptorDensity
Tissue was analyzed for somatostatin receptors using autoradiography with 1251-
Tyr3-SMS 201-995, a tyrosine substituted analog of octreotide (Fig. 3). The ligand
was iodinated and purified according to the method of Reubi and characterized in
standard binding assays [6,9]. Binding in the tested tumors was of the high-affinity
type (KD approximately one nM). The range of somatostatin receptor density
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measured in this study lies between a few dozen fmols/mg protein to 2,000-3,000
fmols/mg protein.
Receptors' autoradiography was performed on 10 ,u cryostat sections, as previ-
ously described in detail [6]. The autoradiograms were quantitatively analyzed by
means of a computer-assisted image processing system, as previously described.
Radioactive polymer standards for iodinated compounds (Amersham Laboratories,
Little Chalfont, England) were used for this purpose [10]. Unless otherwise stated,
the measured density refers to thewhole tumorsection.
The presenceofsomatostatin receptorsin tumorsisrepresentedbyfoursemiquan-
titative categories [6]:
+ + + represents tumors with very strongly positive somatostatin receptor
density (>3,000 dpm/mg tissue equivalent).
++ represents tumors with stronglypositive somatostatin receptor density
(1,000-3,000 dpm/mg tissue equivalent).
+ represents tumors withpositive somatostatin receptor density ( < 1,000
dpm/mg tissue equivalent).
Negative means absence of somatostatin receptors, defined as an optical
density on the films from total binding sections lower than twice the nonspe-
cificbinding.
In VivoHormnonalResponses
Hormonal responsiveness was defined as the maximum reduction in the patholog-
ically elevated hormone after treatment with octreotide. A "major response" was
.50 percent reduction, a "minor response" was 25-49 percent reduction, and "no
response" was <25 percent reduction or increase compared to the hormone level
before treatment.
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RESULTS
Carcinoid Patients
In the 20 patients with carcinoid tumors, the sites of origin of the tumors were as
follows: small intestine, 12; bronchus, four; thymus, one; and unknown, three. The
liver was the site of the biopsy in 17 patients, a lymph node in two, and a breast
nodule in one. Seven ofthe 20 patients had been receiving octreotide chronically for
periods ranging from three months up to 3.8 years. In 18 patients, as an indicator of
response, we measured the 24-hour urine levels of5-HIAA, and, in two patients, we
measured levels ofACTH.
Receptors were present in 16 carcinoid patients (80 percent), and all but one of
these responded clinically with a median reduction in 5-HIAA of63 percent (range,
39-94 percent) (Table 1). In seven patients with positive (+) somatostatin receptors,
the mean reduction in 5-HIAA after treatment with octreotide was 48 percent
(range, 0-94). In one ofthese seven patients, there was no decrease in 5-HIAA, and
there was only a minimal change in flushing and diarrhea. The five patients with
strongly positive (++) somatostatin receptors had a mean reduction in 5-HIAA of
71 percent (range, 49-91). The four patients with very strongly positive (+++)
somatostatin receptors had a mean reduction in their 5-HIAA of67 percent (range,
56-79). One of these four patients' autoradiogram and serial hormone levels are
shown in Fig. 4. There were four carcinoid patients with negative somatostatin
receptors, and three had no clinical or hormonal response to therapy, while one had
only slight clinical improvement and a minimal hormonal response (Fig. 5).
Islet-Cell Carcinoma Patients
All eight patients with metastatic islet-cell carcinoma had biopsy specimens which
were strongly positive in three patients or very strongly positive in five patients for
somatostatin receptors (Table 1, and Figs. 6, 7, and 8). None of the islet-cell
carcinoma patients had been treated with octreotide prior to the biopsy. Symptom-
atic improvement and a .50 percent decrease in at least one ofthe elevated marker
hormone levels was seen in all eight patients. Five ofthe eight patients (cases 21-25
in Table 1) were co-secreting more than one hormone. In three of these five
polyfunctional tumors, all hormones elevated before therapy were reduced after
therapy, but in two of the cases (21 and 24), there was a disparity in hormonal
responsiveness.
Medullary Cancerofthe ThyroidPatients
None ofthe three patientswith medullary carcinoma ofthe thyroid had a decrease
in calcitonin, and all three were initially somatostatin receptor-negative (Fig. 9). Two
ofthe three patients were clinically unresponsive to octreotide, as reflected by stable
or increasing calcitonin levels and new areas of metastases. The third patient had a
mixed response, with transient partial regression ofcervical lymphadenopathy.
DISCUSSION
Since 1984, we have been evaluating the synthetic peptide, octreotide, in patients
with symptomatic, hormonally mediated, neuroendocrine carcinoma syndromes. In
many ways, octreotide mimics the biologic actions of somatostatin, but octreotide is
more resistant to degradation bypeptidases in plasmabecause ofthe presence oftwo
D-amino acids (Fig. 3). This condition results in a biological half-life of three hours
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FIG. 4. Needle biopsy from liver
showing metastaticcarcinoid. A.
Hematoxylin-eosin stain of tumor
section (Bar = 1 mm). B. Auto-
radiogram showing total binding of
1251-Tyr3-SMS 201-995. C.Auto-
radiogramshowingnonspecificbind-
ing of 125I-Tyr3-SMS 201-995 (in the
presence of 10-6 M Tyr3-SMS 201-
995) in an adjacent section.
following subcutaneous injection, compared to the half-life ofsomatostatin, which is
two minutes. This fact means that patients can achieve meaningful therapeutic
benefit by daily administration ofthree subcutaneous injections.
This study establishes a strong correlation between the density of somatostatin
FIG. 5. Tissuebiopsyshow-
ing metastatic carcinoid.
A. Hematoxylin-eosin stain of
tumor section (Bar = 1 mm).
B. Autoradiogram showing
totalbindingof1251-Tyr3-SMS
201-995. C. Autoradio-
gram showing nonspecific
bindingof125I-Tyr3-SMS 201-
995 (in the presence of 10-6
M Tyr3-SMS 201-995) in an
adjacent section.
4,000.000
3,500,000
- 3.000,000
cm 2,500,000
4 2,000.000
W 1,50,000
1,000.000
500.000
0
Baseline Day 3 Month 1 Month 2 Month 3 Month 5
513KVOLS ET AL.
IIII Month Month 2 Month 3 MonthA
Baseline Month 1IMonth 2 Month 3 Month 5
FIG. 6. Needlebiopsyfromliver
showingmetastatic islet-cell carci-
noma. A. Hematoxylin-eosin
stain of tumor section (Bar = 1
mm). B.Autoradiogram show-
ing total binding of 125I-Tyr3-SMS
201-995. C. Autoradiogram
showing nonspecific binding of
1251-Tyr3-SMS 201-995 (in the
presenceof10-6MTyr3-SMS201-
995) in an adjacent section.
receptors in neuroendocrine tumor tissue and the reduction in secretion of hor-
mones after octreotide therapy. In 16 ofthe 17patients with strongly orverystrongly
positive somatostatin receptors (2+ or 3+), octreotide therapy resulted in a major
reduction in the concentration of circulating hormones. There was no major hor-
mone response in any of the seven somatostatin receptor-negative patients. In the
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FIG. 7. Tissuebiopsyshow-
ing metastatic Islet-cell carci-
noma. A. Hematoxylin-
eosin stain of tumor section
(Bar = 1 mm). B.Autora-
diogram showing total bind-
ing of 1251-Tyr3-SMS 201-
995. C. Autoradiogram
showing nonspecific binding
of 125I-Tyr3-SMS 201-995 (in
the presence of 10-6 M Tyr3-
SMS 201-995) in an adjacent
section.
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FIG. 8. Tissue biopsy showing metastatic Islet-cell carcinoma. A. Hematoxylin-eosin stain oftumor
section (Bar = 1 mm). B. Autoradiogram showing total binding of 1251-Tyr3-SMS 201-995. C.
Autoradiogram showing nonspecific binding of 125I-Tyr3-SMS 201-995 (in the presence of 10-6 M
Tyr3-SMS 201-995) in an adjacent section.
FIG. 9. Tissue biopsy
showing metastatic medul-
lary thyroid cancer. A.
Hematoxylin-eosin stain of
tumor section (Bar = 1
mm). B.Autoradiogram
showingtotalbindingof1251-
Tyr3-SMS 201-995. C.
Autoradiogram showing
nonspecific binding of 1251-
Tyr3-SMS 201-995 (in the
presence of 10-6 M Tyr3-
SMS 201-995) in an adja-
cent section.
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TABLE 2
Somatostatin Receptor Status in Patients with Functional Malignant
Neuroendocrine Carcinomas and the Response ofPathologically
Elevated Hormones to Octreotide Therapy
Hormonal Response
Receptor Status Major Minor No Response
+++ positive 9 0 0
++ positive 7 1 0
+ positive 3 3 1
Negative 0 1 6
+++ represents tumors with very strongly positive somatostatin
receptor density (>3,000 dpm/mg tissue equivalent)
++ represents tumors with strongly positive somatostatin receptor
density (1,000-3,000 dpm/mg tissue equivalent)
+ represents tumors with positive somatostatin receptor density
(< 1,000 dpm/mg tissue equivalent)
Negative means absence of somatostatin receptors (defined as an
optical density on the films from total binding sections lower than
twice the nonspecific binding)
seven patients with positive (1+) somatostatin receptors, one was unresponsive
hormonally, and the remaining six were equally divided in the categories of major
and minor hormonal responsiveness (Table 2).
Among the four somatostatin receptor-negative carcinoid patients, two had a
tumor ofbronchial origin, one was a thymic carcinoid, and one originated from the
small intestine. Additional patients will need to be studied before we can draw any
conclusions about thelikelihood ofsomatostatin receptor status in relation to the site
of origin of the carcinoid. Interestingly, the only patient with a receptor-negative
metastasis from a small intestinal carcinoid later underwent palliative resection of
his primary ileal tumor, and analysis of this tissue revealed strongly positive (2+)
somatostatin receptors. The primary tumor was well differentiated, whereas the
metastatic disease in the liver was anaplastic. It is certainly conceivable that
anaplastic tissue might have lost expression of somatostatin receptors. This correla-
tion between more dedifferentiated histology and absence of somatostatin receptors
has been observed previously in breast carcinomas, central nervous system tumors,
and exocrine pancreatic tumors [11-14].
Seven patients had received octreotide therapy prior to having tumor biopsies
analyzed for somatostatin receptors. Two were somatostatin-negative; one was the
patient discussed above with dedifferentiated liver metastases, and the otherwas the
patient with a thymic carcinoid associated with ectopic ACTH production.
The levels ofACTH and cortisol in this patient were not affected by octreotide at
doses ranging from 450-1,500 mcg/day. During a bilateral adrenalectomy for control
ofher Cushing's syndrome, a metastaticretroperitoneal lymph nodewas removed for
analysis of somatostatin receptors. The other patient with a tumor co-secreting
ACTH suffered from a bronchial carcinoid and was also negative for somatostatin
receptors. She also underwent bilateral adrenalectomy to control her Cushing's
syndrome and had normal levels of cortisol at the time of liver biopsy for somato-
statin receptors. The hypercortisol state at the time the biopsy was taken in the one
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patient is noteworthy because of previous observations that corticosteroids cause
downregulation of somatostatin receptors [15,16]. We have never seen suppression
ofectopic ACTH after octreotide therapy in six otherpatients with carcinoid tumors
that were producing ACTH whether or not they had normal cortisols [unpublished
series without somatostatin receptor data]. Additional patients will need to be
studied in order to answer this important question.
Inpatientswithpolyfunctional islet-cellcarcinomas(pathologicallyelevatedplasma
levels of two or more hormones), levels ofone or more hormones may be unaffected
by octreotide while others are markedly decreased. Patient No. 24 (JB) had a major
reduction in gastrin concentration without any significant decrease in VIP levels. In
other patients, one hormone could escape from initial suppression by octreotide
while the other hormones remained suppressed. Patient No. 21 (JK) was somato-
statin receptor-positive and experienced no decrease in insulin level, but he became
euglycemic and has had stability ofhis tumor for the pastyear on octreotide. Patient
No. 23 had been on therapywith octreotide for one yearwith continued suppression
of gastrin, glucagon, pancreatic polypeptide, and 5-HIAA when she developed
hyperinsulinemia and hypoglycemia.
The patient with medullary thyroid cancer who exhibited a mixed response is
particularly interesting. This 62-year-old male had biopsy-proven lymph nodal
metastases and osteoblastic skeletal metastases. Prior to therapy with octreotide, a
liver biopsy positive for malignancy was found negative for somatostatin receptors.
After eight months oftherapywith octreotide at a dose of500 mcg three times daily,
the cervical lymphadenopathy had partially regressed, while the bone scan, liver
metastases, andcalcitoninlevelsremainedstable. Symptomaticsteatorrheaprompted
adosage reduction ofoctreotide,whichwas reduced to250mcgthree timesdailyand
then 150 three times daily over a period ofone week. Toward the end ofthe week of
dosage reduction, the cervical adenopathy rapidly enlarged to more than twice its
original size, causing severe localpain. The node was removed forpalliation, and this
tissue revealed no nodal hemorrhage or necrosis as a cause for the rapid enlarge-
ment. This malignant tissue was positive for somatostatin receptors.
This study did not address alternate mechanisms bywhich octreotide may exert its
hormonal and antiproliferative effects. Growth inhibition with octreotide has been
demonstrated by Reubi in two transplantable tumors. One is a rat chondrosarcoma,
which contains no somatostatin receptors, and the other is a rat insulinoma, which
does contain somatostatin receptors. Whether the anti-neoplastic action of octreo-
tide is a direct effect, or an indirect effect through inhibition of growth hormone,
insulin, or other tumorgrowth factors is unknown.
In conclusion, analysis of somatostatin receptors can be performed on small
specimens of tumor tissue obtained by percutaneous needle biopsy if the specimen
can be immediately frozen at -70°C. Twenty-four of31 (77percent) ofpatientswith
functional neuroendocrine carcinomas had positive somatostatin receptor assays.
The somatostatin receptor status appears to correlate with response to therapywith
the somatostatin analog, octreotide. Somatostatin receptor analysis could be in-
cluded in future prospective studies of these uncommon neuroendocrine tumors to
confirm the correlation ofhormonal responses with the presence ofreceptors and to
determine ifthe interval to progression while on therapy and the overall survival are
related to receptor status.
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